Table 1 Characteristics of prescriptions included in analyses as compared to all prescriptions
Alzheimer’s Disease Cohort | ||
|---|---|---|
Included in Analysis | All Unique Prescriptions | |
Patient Demographics | ||
Age: Mean (SD) | 75.22 (13.91) | 78.86 (12.43) |
Gender (% Female) | 57.64% | 58.12% |
Prescriptions (n (%)) | ||
Donepezil | 57,749 (56%) | 375,576 (50%) |
Galantamine | 1,463 (1%) | 14,210 (2%) |
Rivastigmine | 7,664 (8%) | 61,521 (8%) |
Memantine | 34,555 (34%) | 276,092 (37%) |
Donepezil and Memantine | 1,306 (1%) | 1,935 (0.3%) |
Total | 103,067 | 744,180 |
Days Supply: Mean (SD) | 44.71 (30.00) | 42.37 (31.10) |
Osteoporosis Cohort | ||
Included in Analysis | All Unique Prescriptions | |
Patient Demographics | ||
Age: Mean (SD) | 63.59 (10.32) | 64.54 (10.70) |
Gender (% Female) | 92.66% | 92.82% |
Prescriptions (n (%)) | ||
Abaloparatide | 229 (0.2%) | 2832 (0.4%) |
Alendronate | 80,539 (61%) | 395,836 (56%) |
Alendronate/Cholecalciferol | 120 (0.1%) | 964 (0.1%) |
Denosumab | 3,280 (2%) | 36,970 (5%) |
Ibandronate | 18,585 (14%) | 90,178 (13%) |
Raloxifene | 16,704 (13%) | 102,461 (14.5%) |
Risedronate | 10,766 (8%) | 57,811 (8%) |
Teriparatide | 1,362 (1%) | 17,624 (2%) |
Zoledronic Acid | 185 (0.1%) | 1,734 (0.25%) |
Romosozumab-aqqg | 3 | 35 |
Total | 131,773 | 706,445 |
Days Supply: Mean (SD) | 60.65 (33.67) | 62.72 (37.21) |